Formulation contract manufacturing — Business MegaBrands 2026–27
Formulation contract manufacturers produce finished medicines, such as tablets, capsules, syrups and injectables, which other pharmaceutical companies then sell under their own brands. In India this is often called third-party or loan-licence manufacturing. The model lets marketing-led pharma companies launch products without building plants, and concentrates production in facilities built to meet regulatory standards.
Slot BMB-175 · Contract Development & Research · 3 brands in contention · Business MegaBrand: to be announced in 2027
Brands in contention
Listed alphabetically. The order does not reflect evaluation.
| Company | MegaBrands 501 |
|---|---|
| Akums Drugs & Pharmaceuticals | |
| Innova Captab | |
| Windlas Biotech |
How this category is evaluated
Every brand in this category is assessed on WCRC's 50-parameter brand evaluation model, across five pillars: Brand Positioning & Recall, Trust & Sentiment, Product, Innovation & Delivery, Sustainability, Governance & ESG, and Digital & Financial Soundness. Scores are compared within the category, and the brand with the strongest result is named the Business MegaBrand. Read the methodology
Frequently asked
Which are the leading third-party pharma manufacturers in India?
In the Business MegaBrands 2026–27 cohort, the brands in contention for formulation contract manufacturing are Akums Drugs & Pharmaceuticals, Innova Captab, and Windlas Biotech. This is a list, not a ranking. WCRC will name one Business MegaBrand after its independent 50-parameter evaluation of every brand in contention.
Other categories in Contract Development & Research
All of Pharma, Life Sciences & Medtech · The 2026–27 cohort
Cite this page: WCRC, Business MegaBrands 2026–27, Formulation contract manufacturing (Slot BMB-175), https://www.mostvaluablebrands.com/business-megabrands/2026-27/pharma-life-sciences-and-medtech/formulation-contract-manufacturing/, accessed [date].
WCRC network: WCRC International · WCRC Leaders